Does biologic therapy improve asthma control for patients with severe asthma?
Biologic therapies are a major advance for people with severe asthma that remains uncontrolled despite high-dose inhalers and other standard treatments. These medications target specific immune pathways driving airway inflammation. Multiple studies show that biologics can substantially improve asthma control, reduce the number of severe attacks (exacerbations), and improve quality of life. The evidence is strongest for patients with certain inflammatory patterns, but newer biologics are expanding options for more patients.
What the research says
A large systematic review of 49 studies involving 2,292 patients who switched biologics found that the switch led to a significant reduction in asthma exacerbations (standardized mean difference -1.03), fewer emergency department visits and hospitalizations, and improved asthma control scores (ACT improved by 5.18 points, ACQ improved by -1.05 points) 1. Lung function also improved, with an increase in FEV1 of 0.18 liters 1. The most common reason for switching was suboptimal asthma control (77% of cases) 1.
A 2025 state-of-the-art review confirms that currently available biologics — targeting immunoglobulin E, interleukin-5/IL-5Rα, IL-4Rα, and thymic stromal lymphopoietin — play a significant role in reducing exacerbations, hospitalizations, and the need for maintenance oral steroids, while improving quality of life in severe asthma 8. This evidence comes from randomized controlled trials, extension studies, meta-analyses, and real-world data 8.
A study of 113 patients with severe asthma categorized by baseline airway inflammation found that after 6 and 12 months of biologic therapy, patients with eosinophilic and mixed granulocytic patterns showed improvements in asthma control and exacerbation rates 3. Most patients with neutrophilic inflammation also had elevated type 2 biomarkers, suggesting they may benefit from certain biologics 3.
A narrative review highlights tezepelumab, a biologic targeting TSLP, which is approved for severe asthma without requiring a specific phenotype or biomarker eligibility, including type 2-low disease 2. This expands treatment options for patients who previously had limited biologic choices 2.
A 2023 Lancet Seminar notes that biologic therapies have moved severe asthma management into the precision medicine era, with clinical ambitions shifting toward disease remission 6. A 2025 study on mepolizumab found that after 12 months, patients had significant improvements in lung function, Asthma Control Test scores, and a decrease in severe exacerbations 7. The study also showed reductions in airway remodeling markers like sub-basement membrane thickness and airway smooth muscle area 7.
Asia-Pacific experts have proposed a definition of clinical remission in severe asthma that includes elimination of exacerbations and oral corticosteroid use, good symptom control, and lung function criteria, reflecting the evolving treatment landscape with biologics 4.
What to ask your doctor
- Based on my asthma type and biomarker levels (like blood eosinophils or FeNO), which biologic might be most effective for me?
- What improvements in asthma control, exacerbation rate, and lung function can I realistically expect from biologic therapy?
- How long after starting a biologic should I expect to see improvement, and how will we monitor my response?
- If the first biologic doesn't work well enough, is switching to another biologic an option for me?
- What are the potential side effects and long-term safety considerations for the biologic you recommend?
This question is drawn from common patient questions about Pulmonology & Critical Care and answered using cited medical research. We do not provide individualized advice.